Diagnosis and treatment of lymphangioleiomyomatosis (LAM) from the PEComa group

ABSTRACT

Lymphangioleiomyomatosis (LAM) is a rare, proliferative lung disease, leading to progressive damage of their structure and is a member of the PEComa neoplasm family (perivascular epithelioid cell tumors). In the patients, solid-cystic masses described as lymphangioleiomyoma or extrapulmonary LAM (E-LAM) can occur. E-LAM foci have been described in the mediastinum, supraclavicular lymph nodes, the liver, walls of the small and large intestine, the pancreas, mesentery. E-LAM masses can attain very large sizes — tumors 15–22 cm long have been described. On the basis of positive results of clinical trials sirolimus, a drug from the group of mTOR kinase inhibitors, was registered by the Food and Drug Administration (FDA) in May 2015 as the first and currently only drug for systemic LAM therapy. Sirolimus use is recommended in patients with LAM, accompanied by rapidly progressing deterioration of respiratory system function or FEV₁ ≤ 70% predicted value and in patients with pleural lymph exudate before applying invasive methods of treatment.

Key words: lymphangioleiomyomatosis, sirolimus

Introduction

Lymphangioleiomyomatosis (LAM) is a rare, proliferative lung disease leading to progressive damage to their structure with the formation of numerous small cysts and lymph accumulation in the pleural cavity [1]. At its basis is the multifocal proliferation of smooth muscle cells and perivascular epithelioid cells, (PECs); in LAM they are also designated LAM cells in the lung interstitium and is therefore included in the family of PEComa type neoplasms (perivascular epithelioid cell tumors) [2]. The PEComa group also includes angiomylipoma (AML), clear-cell sugar tumor (CCST) — pulmonary and extrapolmonary forms (primary extrapolmonary sugar tumor, PEST), clear-cell myomelanocytic tumor (CCMMT) and primary cutaneous PEComa, CCCMT — cutaneous clear cell myomelanocytic tumor and PEComa NOS (not otherwise specified) [3]. Pulmonary LAM (P-LAM) occurs in two clinical forms: associated with tuberous sclerosis [Bourneville-Pringle disease, tuberous sclerosis complex (TSC)] — a genetic syndrome caused by inactivating germline mutations in the TSC1 and TSC2 genes, characterized by the occurrence of many tumors of the hamartoma type, perturbations of the nervous system, including epileptic seizures, autism and intellectual disability of various degrees [4], and as a sporadic form — sporadic LAM (S-LAM), in women with no predisposing factors [5]. In addition to pulmonary manifestation of LAM, in these patients, numerous irregularities are observed in the lymph system outside the chest such as perturbations of the patency of the thoracic duct, lymph exudate in the retro-orbital space and pelvis, or lymphadenopathy [5]. Moreover, in rare cases, there is a proliferation of pathological lymph vessels infiltrated by LAM cells, leading to an obstruction of their lumen and accumulation of lymph resulting in the formation of solid-cystic masses described as lymphangioleiomyoma or extrapolmonary LAM (E-LAM) [6].
Frequency of occurrence

The frequency of occurrence of lung LAM differs depending on the clinical type — pulmonary LAM is found in 30–50% women and approximately 10% men with tuberous sclerosis [7, 8], whereas the sporadic form occurs in one woman out of 200–400 thousand [5, 7]. Lymphangioleiomyomatosis concerns almost exclusively women of reproductive age — the median age at diagnosis is in the range of 35–41 years [9–12]. Pleural LAM is rarely diagnosed in postmenopausal patients — of note here is the often occurring information about the use of hormonal replacement therapy [12, 13]. Single cases have been described of the occurrence of the disease in children and men without predisposing genetic factors [14–16]. Extrapulmonary perturbations within the lymphatic system are found often in patients with the pulmonary LAM form — perturbations in the patency of the thoracic duct are found in over 70%, lymph exudate in the retroperitoneal space is observed in 30% of the cases [17]. Lymphangioleiomyoma is less common — in 10–21% of patients with pulmonary S-LAM [12, 17–19] and is often accompanied by a swelling of lymph nodes within the abdominal cavity, ascites and a broadening of the thoracic duct [18]. It seems that the frequency of occurrence of lymphangioleiomyoma in patients with the pulmonary form of LAM increases with the severity of its course [18], but they are not more common in patients with tuberculous sclerosis — in a retrospective analysis from the Mayo Clinic, among 403 patients with TSC, E-LAM occurred in only 3 [20]. In the analysis of autopsy material or material obtained from gynecological surgery in 10 female patients with the pulmonary form of LAM, the presence of small LAM foci in the uterus, adnexa or broad ligament of the uterus was observed in as many as 90%, and in 80% — the occupation of the lymph nodes in the retroperitoneal space [21]. It is not clear whether the presence of E-LAM foci predisposes to the development of the pulmonary form of LAM. In a large retrospective analysis of material obtained from 1732 patients without a history of LAM (median age 56 years), who underwent gynecological surgery with lymphadenectomy, extrapulmonary LAM foci were found in 8 patients [22]. In one of them a pulmonary form of LAM was diagnosed, 7 years after the gynecological surgery whereas the remaining women did not have a LAM relapse in any form (median observation 26 months) [22]. In a similar analysis among 19 patients in whom asymptomatic extrapulmonary LAM had been detected occupying the uterus and pelvic and paraaortal lymph nodes during an average 33 month observation none developed the pulmonary form [23]. Besides the description of cases concerning women with LAM foci in paraaortal and pelvic lymph nodes, in whom pulmonary LAM did not occur nor tuberculous sclerosis [24, 25], descriptions are also available in which extrapulmonary LAM was the first symptom of the development of the pulmonary LAM form, which if it occurs is most commonly diagnosed within about 2 years from the diagnosis of the extrapulmonary form [6, 26–31].

Anatomy and clinical picture

Pulmonary LAM leads to progressive destruction of the lung parenchyma and its replacement by numerous small cysts, causing a progressive respiratory deficiency [7]. In the course of LAM exercise tolerance is progressively limited as well as everyday physical activity to a degree greater than in for example chronic obstructive pulmonary disease [32]. Among the most common early symptoms of the disease are: dyspnea, persistent coughing and hemoptysis [7, 11, 12]. Dyspnea at rest and the need for oxygen therapy appears in most patients within 10 years from the diagnosis [33]. The course of the disease is complicated by recurring pneumothorax, occurring in about 5% of the patients per year from the moment of diagnosis; additionally, in about one-half of the cases they are the first symptom of developing LAM [3, 12, 34]. Moreover, because of the perturbation of lymphatic vessel patency, there are lymph exudates in the pleural cavity causing an intensified dyspnea and chest pain [35]. LAM is also a rare cause of occurrence of pulmonary hypertension (about 7.6% patients LAM) [9].

Lymphangioleiomyoma is most commonly localized in the retroperitoneal space and the uterus and in surrounding lymph nodes [6, 24, 27]. Moreover, E-LAM foci developing in the mediastinum [36], supraclavicular lymph nodes [37, 38], liver [39], walls of the small and large intestine [40, 41], pancreas [26, 42], mesentery [43] have been described. E-LAM masses can reach very large sizes — cases of tumors with the greatest length 15–22 cm have been described [18, 44–46] and can extend along lymph vessels — coming from the retroperitoneal space to the chest [19], and further even along the neck along with the sternocleidomastoid muscle [47].

The symptoms of lymphangioleiomyoma presence occur in about 55–60% patients [6, 18] and the most commonly are: pain in the vicinity of the tumor [26, 29, 46] and bleeding from the reproductive system in the case of LAM localized in the uterus [24, 48, 49]. Symptoms associated with the pressure of the tumor mass on neighboring organs are also frequently observed: dyspepsia, bloating and symptoms of obstruction of the alimentary tract [46], hydronephrosis or edema and paresthesia of the lower extremities [46, 50]. Lymphangioleiomyoma localized in the mediastinum may cause Horner syndrome, lymph exudates to the pleural cavity and heart rhythm perturbations [6, 18]. If LAM cells infiltrate the ureters, chyluria occurs [51], whereas the occupation of Vater’s papilla may lead to cholestasis [45]. In the case of large lymphangioleiomyomas, ascites...
linked to a large lymph volume may be observed [6] or bleeding from the tumor to the abdominal cavity [52]. Symptoms due to pressure on neighboring organs such as: bloating, pain in the vicinity of the tumor, polakuria, edema and paresthesia of the lower extremities or constipation are more intense during the day [18]. This is associated with an increase in tumor volume during the day due to greater flow of lymph through the abdominal cavity and the pelvis after meals and during daily activity, and an increase in hydrostatic pressure in the erect position [18, 27]. The increase in volume during the day is 140% on average [18]. Changes in lymphangioleiomyoma volume during the menstrual cycle have also been described [53].

**Diagnosis**

According to the recommendations of the European Pulmonological Society, the gold standard in LAM diagnosis is a lung biopsy and high-resolution computer tomography of the chest [7]. Characteristics additionally favoring this diagnosis are: angiomylipoma currently/in the patient’s history, lymph exudates within the chest and abdominal cavity, tuberous sclerosis, the presence of lymphangioleiomyoma or microscopically detected occupation of lymph nodes by LAM cells [7]. In the recommendations of the American Thoracic Society/Japanese Respiratory Society from 2017, the following are also included among these properties: plasma concentration of vascular epithelial growth factor D (VEGF-D) ≥ 800 pg/mL and the presence of LAM cells in a cytological examination of the lymph exudates in the pleural cavity [54]. Because LAM is exceedingly rare in males, the final diagnosis should be made in each case on the basis of a typical result of a lung biopsy [7]. A transbronchial biopsy has been shown to be a relatively safe method in the group of LAM patients [55].

High-resolution computer tomography is the examination of choice both in the diagnostic process as well as to observe disease progression [7]. Among typical radiological changes observed in all patients are numerous, small round cysts in the lung (2–5 mm diameter), equally distributed within the lung parenchyma [11]. Because of the frequent co-occurrence of LAM and renal angiomylipoma computer tomography with an abdominal cavity and pelvic contrast is recommended, and in the case of contraindications for contrast use — a magnetic resonance analysis [7].

Lymphangioleiomyoma in computer tomography most commonly takes the form of well-defined, solid-cystic lesions, with walls of different thickness and numerous septa [26, 27, 46]. Less commonly a solid or only cyst-like character is observed [27]. The lesion is generally delimited but a few lymphangioleiomyomas with an infiltrating type of growth are observed [18]. Solid tumors have a density similar to the liver (59–71 HU), cyst-like lesions a lower one (3–25 HU), corresponding to lymph accumulation [18]. The cyst walls may become more pronounced after contrast [17]. Lymphangioleiomyoma under magnetic resonance shows differentiated values of signal both in T1 and in T2 exposure [38, 44, 49, 50]. In PET a small uptake of glucose is observed [26]. In ultrasound E-LAM can give the appearance of an isoechogenic, hypo- and hyperechogenic lesion, not permitting its differentiation from other neoplastic lesions localized in the retroperitoneal space and the pelvis [27].

LAM is also associated with an increased risk of meningioma development, therefore in the case of symptoms from the central nervous system magnetic resonance of the head is justified [7]. Patients with LAM should also be under the care of a genetic counseling facility — TSC is characterized by a broad range of phenotypes and poorly clinically expressed characteristics of this syndrome may lead to incorrect classification of the case as sporadic [7].

**Morphology**

The typical appearance for LAM encompasses the occurrence of numerous cysts in the parenchymal tissue of the lungs and multifocal proliferation of immature smooth myocytes and perivascular epitheliod cells (PECs), known in the case of lymphangioleiomyoma as LAM cells [7]. Foci of proliferation for LAM cells and myocytes are most commonly located around lymph vessels, interlobar septae and the pleura [3]. Within LAM cysts smaller fusiform cells are localized more centrally, whereas epithelioid cells with abundant cytoplasm are localized mainly at the periphery [56]. Cytological atypia and division patterns are generally not present [57].

On the basis of the intensity of two morphological changes typical for LAM: the occurrence of cysts and intensification of LAM cell proliferation within lung biopsy material, Matsui et al. (2001), elaborated a division into III histologic severity grades (LHS, histologic severity of LAM) [34]. The percentage of lung tissue occupied by the described lesions viewed under a small magnification was qualified as follows: LHS1 < 25%; LHS-2: 25–50% and LHS-3 > 50% [34]. The authors also showed a strong correlation of the grade of LHS severity with 10-year overall survival, which was: 100%.
Figure 1A–D. Retroperitoneal LAM with infiltration of lymph node — in the order of staining HE, SMA, HMB-45, progesterone receptors [100×]

74.4% and 52.4%, respectively in w LHS-1, LHS-2 and LHS-3 [34]. LHS is currently an acknowledged prognostic factor in pulmonary LAM [58].

Lymphangioleiomyoma is generally described as lesions well delimited from surrounding tissues [21, 26], with the presence of a fibrous capsule [57]. Infiltration of LAM cells beyond the capsule is rare [6]. LAM foci in the uterus are an exception, they are frequently poorly separated from unaffected smooth uterine muscle coat [21, 24]. Differential diagnosis of E-LAM within the uterus encompasses myoma, leiomyosarcoma, endometrial stromal sarcoma or paraganglioma [48]. Lymphangioleiomyomas similarly as the pulmonary form is composed of fusiform and epithelioid LAM cells with round and oval nuclei with an abundant slightly acidophilic cytoplasm [6, 24, 50]. These cells form nests — resembling the so-called „zellballen” described in phaeochromocytomas [26], separated by slot-like vessels with thin walls lined with endothelial cells [50], which may undergo hyalinization [21, 24, 26]. Typically necrosis and blood extravasation to the tumor are not observed [6, 21, 26, 46]. In most cases the mitotic activity is low [6, 21], in some cases, up to 4 figures for 10 visual fields were observed [24, 37]. A fairly common finding are small clusters of reactive lymphocytes, resembling lymph nodules [6].

LAM cells are characterized by the simultaneous expression of melanocyte (HMB-45, Melan A, MART1) and smooth muscle (SMA, desmin, actin) markers (Fig. 1) [59, 60]. The expression of HMB-45 is observed in all cases, and the percentage of cells showing the expression of this marker is variable — it is in general 20–40% and concerns predominantly epithelioid cells [11, 56, 60, 61]. In almost all cases the expression of the estrogen (ER) and progesterone (PR) receptor also occurs — mainly within fusiform cells [56], and in general PR expression is stronger [62]. Other markers useful in the differential diagnosis are β-catenin and E-cadherin and cathepsin K, whose expression has been observed in all analyzed cases [56, 63, 64]. The co-occurrence of the expression of lymph vessel endothelium markers is also characteristic: podoplanin (D2-40), PROX1, VEGFR-3 and LYVE1, which occurs both in cells lining lymph vessels and in the LAM cells themselves [56]. Among less typical markers is the epithelial growth factor receptor (EGFR), whose expression was observed in about one-half of cases [56]. Kobayashi et al. (2018) have also demonstrated the cytoplasmic expression of EGFR/ErbB-1 and HER4/ErbB-4 in LAM cells [65]. Maisel et al. (2018) described the strong expression of the programmed death-ligand 1 (PD-L1) in preparations from lung biopsies from 6 patients with LAM, which was greater in preparations from pulmonary nodules than in tissue from healthy lungs [66]. They also found the presence of T lymphocytes showing the expression of programmed death-ligand 1 (PD-1) receptor, infiltrating
LAM foci [66]. In the case of lymphangioleiomyoma, LAM cells show the expression of a similar marker profile: HMB45 — particularly in epithelial cells [6], Melan A, calponin, SMA, desmin, nuclear expression of ER and PR [6, 24, 46, 50]; moreover expression of $\beta$-catenin [35], E-cadherin [67], MiTF [25] and in the lymph vessel endothelium: CD34, podoplanin, CD31, and VEGFr-3 [21, 24, 26, 43].

Genetics

Similarly, as other proliferative diseases from the PEComa family, lymphangioleiomyoma has a higher frequency of occurrence in patients with tuberous sclerosis — characterized by the presence of germline inactivating mutations and loss of heterozygosity (LOH) in the 16p13.3 region, in the TSC2 locus, encoding the tuberin protein and in the 9q34 region, locus TSC1, encoding the hamartin protein [8, 68]. Tuberin has an inhibiting action on the signalling protein Rheb — a homolog of the Ras protein (Ras homolog enriched in the brain — Rheb), which in turn is a known activator of the mTOR serine-threonine kinase [69]. Hamartin forms a complex with tuberin, stabilizing it and protecting it from degradation in proteosomes [70]. Excessive activation of the Rheb protein due to the loss of function of one of these two proteins leads to activation of the mTORC1 pathway, increased synthesis of proliferation stimulating proteins and angiogenesis resulting in the presence of numerous tumors of the PEComa type in patients with tuberous sclerosis [69]. The pulmonary form of LAM is found in approximately 30–50% women and in approximately 10% men with tuberous sclerosis, these are more commonly patients with mutations within TSC2 [8, 71]. Similarly, somatic inactivating mutations and loss of heterozygosity in the TSC1 and TSC2 genes are observed in LAM cells obtained from patients with the sporadic LAM form though as this form is rare there are no analyses of large groups of patients [72]. Badri et al. (2013) analyzed material obtained from 10 patients with sporadic LAM, showing that in as many as 8 of them LAM cells showed perturbations within the TSC2 locus, moreover, in 4 of them complete loss of tuberin occurred because of loss of heterozygosity and a mutation in the second allele (3 cases) and two inactivating mutations in both alleles simultaneously in one case [73]. In the paper by Fujita et al. (2015), inactivating somatic TSC1/TSC2 mutations were detected in LAM cells in 6 out of 9 patients with LAM [74]. Among other genetic changes observed in patients with lymphangioleiomyoma are: germline mutations within BARD1, BLM and BRCA2 [14] and EGFR amplification [56], however, their role in LAM pathogenesis has not been fully analyzed.

Evaluation of the stage of the pulmonary form of LAM and factors affecting the severity of its progression

Among analyses of the functioning of the respiratory system whose results correlate with the irregularities observed in radiological and histopathological analyses and which change with disease progression are: analysis of the coefficient of lung transfer for carbon monoxide (TLco) and a spirometric analysis — especially the measurement of the forced expiratory volume in 1 second (FEV1) [58]. In the first evaluation of the degree of progression of the disease TLco and spirometric analysis with a bronchodilatory test are recommended [7]. Moreover, in patients from whom a lung biopsy was obtained a histological evaluation of the progression in the LHS scale, which was described earlier, is performed [58]. FEV1 and TLco measurements should be repeated every 3–6 months in order to evaluate the progression of the disease and the response to treatment and in the case of stable results, the control analyses can be reduced to annual ones [7]. In patients in the initial stage of the disease in general deviations are not observed in gasometric blood analysis, it is used as an indication of indications for oxygen therapy and lung transplantation in patients with advanced disease [7]. An exercise test and a 6-minute marching test (6MWT) find application in the evaluation of the effect of the disease on general performance and response to treatment [58]. The pulmonary LAM form is characterized by a milder course in patients with tuberous sclerosis, in comparison to the sporadic form [7, 58]. Moreover, patients in whom the first LAM symptoms are hemoptysis and dyspnea have a worse disease than those in whom LAM was diagnosed because of pneumothorax, which may be associated with the delay in diagnosis in the first group [58]. A tendency of LAM to progress more slowly in post-menopausal women has been indicated [75]; in the analysis by Gupta et al. (2019) the change in FEV1 in pre-menopausal women was on the average –118 mL/year, whereas in postmenopausal women it was –74 mL/year (p = 0.003) [76]. A recently described prognostic factor in lymphangioleiomyoma is the plasma level of vascular endothelial growth factor D (VEGF-D), which is much higher in patients than in the healthy population, especially in patients with tuberous sclerosis [77]. A high level of VEGF-D (over 800 pg/mL) was correlated with a more rapid rate of deterioration of FEV1 values [78] and the presence of lymph exudates to the pleural cavity and the number of pulmonary cysts [77]. Other markers which have been associated with the severity of the course of pulmonary LAM are: the concentration of extracellular matrix metalloproteinases (MMP) in urine [58], the plasma concentration of vitamin D binding protein (VTDB) [79, 80], VEGF-3 receptor and chemokine CCL21 [81].
or the expression of the receptor of the human epithelial growth factor 3 (HER3) w LAM cells [61].

**Pulmonary LAM treatment**

Respiratory rehabilitation encompassing aerobic exercises and exercises for strengthening the breathing muscles exerts a proven, favorable effect on the evaluation of life quality, the 6MWT result, the feeling of dyspnea and the level of everyday activity of LAM patients [82]. By analogy to the procedure in chronic obstructive pulmonary disease, it is recommended that LAM patients be covered by prophylactic vaccinations against pneumonia diplococcus and influenza and because of the frequent occurrence of osteoporosis, patients with LAM should undergo periodic densitometric analyses [7]. LAM is associated with an increased risk of pneumothorax, which occurs in about one-half of patients at the moment of diagnosis and in over 60% of patients in the course of the disease, with a tendency to frequent recurrences [7]. Factors additionally increasing the risk of pneumothorax are pregnancy and flying [7, 83]. Pleurodesis is effective in preventing recurring pneumothorax; the analysis by Gonano et al. (2018) of a group of 145 patients indicated that pleurodesis prevented its occurrence with a probability of 82%, 68% and 59% after one, 5 and 10 years, respectively after the procedure in comparison with 55%, 46% and 39% among patients who did not undergo the procedure (p = 0.026) [83]. In the case of abundant lymph exudates to the pleural cavity a diet low in fat is recommended, and if clinical symptoms occur (dyspnea, coughing, chest pain) — traditionally draining of the pleural cavity through thoracentesis is applied [7], however, in the light of new evidence before starting treatment by invasive methods an attempt to control the symptoms by systemic treatment with sirolimus is recommended [5, 35, 84]. In advanced stages of LAM, in patients considered to be class III–IV on the NYHA scale with hypoxemia at rest, lung transplantation can be applied [7]. Average time from diagnosis to the transplantation varies in papers from various centers in the range of 4–5 years [85, 86]. In a large retrospective analysis of data concerning the course of the disease in 138 patients with LAM who had undergone a lung transplantation 1-year, 5-year and 10-year overall survival after the procedure were: 94%, 73% and 56%, respectively, and the causes of death were most commonly: bronchiolitis obliterans and chronic transplant rejection [87]. Such parameters as the presence of lung hypertension and the 6MWT distance before the procedure, the patient’s age, time of organ ischemia during the procedure or transplantation of one or both lungs did not affect overall survival after the procedure [87]. In the analysis by Reynaud-Gaubert et al. (2008), summing up the results of lung transplantation of several French transplantation centers 1-year, 5-year and 10-year overall survival after the procedure were 79.6%, 74.4% and 64.7%, respectively [85]. Baldi et al. (2017) obtained similar results in an analysis encompassing 11 patients with LAM, the probability of surviving one, three and five years after lung transplantation was 90%, 90% and 75%, respectively [86]. There are rare descriptions of patients with a LAM recurrence in the transplanted lung [85, 88].

In recent years a breakthrough has occurred in systemic lymphangioleiomyomatosis treatment, which for many years was resistant to anti-estrogen therapy (removal of ovaries, use of meastroxypregosterone or selective estrogen receptor modulators) whose efficacy had finally not been proven [89]. No efficacy was demonstrated for treating LAM using doxycycline [5] or an aromatase inhibitor — letrozole [90]. On the basis of positive results of clinical trials, sirolimus, a drug from the group of mTOR kinase inhibitors was registered by the Food and Drug Administration (FDA) in May 2015 as the first and currently the only drug for systemic LAM treatment [5]. According to the guidelines of the American Thoracic Society/Japanese Respiratory Society, sirolimus is indicated in patients with LAM, accompanied by a rapidly deteriorating function of the respiratory system or FEV1 ≤ 70% of the predicted value. In patients with symptomatic pleural lymph exudates, before using invasive treatment methods [5]. Clinical trials concerning the use of mTOR inhibitors (sirolimus, everolimus) in treating lymphangioleiomyomatosis are summarized in Table 1 — without taking retrospective analyses into consideration.

A randomized, multicenter, placebo-controlled, double-blind phase III clinical trial MILES (Multicenter International Lymphangioleiomyomatosis Efficacy And Safety Of Sirolimus), is so far the largest clinical trial concerning the use of sirolimus in LAM [91]. 89 patients were randomly divided into 43 receiving placebo and 46 sirolimus p.o. at an initial dose of 2 mg/d, and then established to maintain the serum concentration of the drug at a level of 5 to 15 ng/mL [91]; this dosage was accepted as a standard in successive trials [84, 92, 93]. After 12 months of treatment in the group receiving sirolimus FEV1 stabilization was observed (+1 ± 2 mL/month) with worsening FEV1 at 12 ± 2 mL/month in the placebo group (p < 0.001). In the treatment group improvement was also observed in forced vital capacity (FVC), exercise tolerance, evaluation of the quality of life and a decrease in the serum concentration of VEGF-D in comparison with the placebo group. After finishing taking sirolimus, FEV1 decreased at the same rate in both groups, which suggests that sirolimus therapy does not stop the progression of the disease when therapy is terminated, but also does not speed up this process [94].
| Author, year | Trial type | N | Age-years | TSC % | Drug | Drug concentration/dose | Length | FEV₁ changes | Other effects |
|-------------|-----------|---|-----------|-------|------|------------------------|--------|--------------|--------------|
| Bissler et al. 2008 *[105] | Single center, open | 25 (18 LAM) | – | 66.7 | S | 10–15 ng/mL | 12 months + 12 months observation | At the end of treatment: +118 ± 330 mL vs. wp | ↑ FVC, ↓AML volume |
| Dabora et al. 2011 *[106] | Multicenter, open | 36 (21 LAM) | 34 | 100 | S | 9–15 ng/mL | 52 weeks | No changes vs. wp | ↓AML volume, ↓VEGF-D, ↓number of skin changes |
| Davies et al. 2011 *[107] | Multicenter, open | 16 | – | 33 | S | 3–10 ng/mL | 24 months | –76 ± 52 mL/r | ↓AML volume, ↓QoL, ↓VEGF-D, ↓FRC |
| McCormack et al. 2011 *[91] | Multicenter, randomized, double blind, placebo control | 89 | 45.4 | 9 | S | 5–15 ng/mL | 12 months + 12 months observation | Sirolimus: +1 ± 2 mL/month placebo: −12 ± 2 mL/month | ↑FVC, ↑QoL, ↑VEGF-D, ↓FRC |
| McCormack et al. 2011 *[91] | Multicenter, randomized, double blind, placebo control | 118 (29 LAM) | 31 | 96 | E | 10 mg/d E: average 38 weeks placebo: average 34 weeks | Everolimus: −1% wp placebo: −4% wp | ↓AML volume, ↓number of skin changes |
| Nuttall et al. 2014 [109] | Single center, open/observational | 10 | 42.4 | 20 | S | 5–10 ng/mL | 12.1 ± 2.81 months | After 6 months: +345 ± 58 mL | ↑ FVC, ↑DLco, ↑6MWD |
| Taveira-DaSilva et al. 2011 [84] | Single center, open/observational | 19 | 41 | 0 | S | 5–15 ng/mL | 2.5 years | Before treatment: −2.8% ± 0.8% wn/r sirolimus: +1.8% ± 0.5% wn/r time of observation | ↑FVC, ↑ΔDLco, ↑chylothorax |
| Bee et al. 2018* [111] | Prospective, cohort | 47 | 43.6 | 19 | S | 1–2 mg/d | Average 35.8 months | In the whole group: +11 mL/r (od +254 do −148 mL/r) | – |
| Taveira-DaSilva et al. 2018 [112] | Single center, open | 25 | 40.6 | 8 | S | 5–15 ng/mL | 54 ± 19.2 months | Before treatment: −7.4% ± 1.4% wn/r sirolimus: −0.3% ± 0.5% wn/r | ↓AML diameter, ↓VEGF-D, ↓DLco, ↓chylothorax |

BP — blood pressure; DLCO — lung diffusion capacity for carbon dioxide; DN — adverse effects; DDO — lower respiratory tract; DO — respiratory tract; GDO — upper respiratory tract; FEV₁ — first second forced vital capacity; FVC — forced vital capacity; Qo — the quality of life; TC — total cholesterol; TG — triglycerides; WBC — white blood count; ZUM — infection of the urinary tract; wn — predicted value; wp — initial value; *trial included in meta-analysis by Gao et al. (2018) [98]
In the MILES trial, VEGF-D serum concentration was indicated as a negative prognostic factor but at the same time as a positive predictive factor for response to sirolimus treatment [95]. A higher VEGF-D level at the beginning of the trial was associated with a better response to treatment in the group receiving sirolimus (improvement in FEV₁ and FVC values), but at the same time a more rapid decrease in the value of these parameters in the placebo group [95]. In the last performed analyses a positive effect of sirolimus on burdensome LAM complications such as lymph exudates to the pleural cavity and recurring pneumothorax was also observed. In the trial by Zhou et al. (2018) in 5 analyzed patients with recurring pneumothorax in spite of pleurodesis, taking sirolimus in doses ensuring the maintenance of the drug concentration in serum at a level 3–10 ng/mL, no recurrences of pneumothorax were observed during the whole time of treatment [96]. However, interruption of therapy or a decrease of the blood concentration of the drug below 3 ng/mL resulted in recurrence of pneumothorax in 2 patients during 2 and 3 year-long observation [96]. In an observational trial by Taveira-DaSilva et al. (2011) planned to evaluate the benefit of using sirolimus in patients with a severe course of LAM and abundant lymph exudates in the pleural cavity in all 12 patients a complete or almost complete reduction of the volume of the accumulating liquid took place which allowed draining of the pleural cavity to be stopped in 2 of them [84]. In two retrospective analyses the effectiveness of sirolimus at a lower dose (target drug concentration in serum below 5 ng/mL) in comparison with a standard dose (drug concentration in serum 5–15 ng/mL on the basis of the MILES trial), was evaluated, yielding contradictory results [10, 97]. Ando et al. (2013) showed an improvement in the function of the respiratory system and withdrawal of lymph exudates in patients treated with low doses, to a degree comparable with the results of trials using the higher dose [10]. However, Yoon et al. (2018) showed lower effectiveness of lower doses of sirolimus, whose use at the same time did not lead to a decreased frequency of undesirable adverse effects [97]. In a meta-analysis by Gao et al. (2018), encompassing 7 clinical trials concerning the use of sirolimus in LAM, a significant improvement of FEV₁ and FVC was confirmed in treated patients – the weighted average of differences was: 0.15 l (95% CI: 0.08–0.22, p < 0.01, I² = 0%) for FEV₁ and 0.221 (95%: 0.11–0.32, p < 0.01, I² = 0%) for FVC [98]. However, no improvement of the 6-minute walk test nor the diffusion capacity of the lungs for carbon dioxide was observed. The accumulated frequency of occurrence of adverse events was: 50% for stomatitis, 40% for hyperlipidemia, 23% for headaches, 20% for bone marrow suppression and 19% for diarrhea [98]. Among frequently mentioned adverse effects of sirolimus are also respiratory tract infections, but sirolimus was not shown to increase their frequency with respect to the population of patients with LAM not using systemic therapy [99]. Sirolimus is currently the only drug whose use in LAM is recommended in the guidelines of the American Thoracic Society/Japanese Respiratory Society, in the light of the lack of convincing evidence for the effectiveness of other substances [5]. Preclinical and clinical trials are also being conducted on autophagy inhibitors [100], statins [101], hydroxychloroquine [102], a synthetic flavonoid — Proxison — an antioxidant normalizing mitochondrial metabolism, which showed synergy with sirolimus in inhibiting LAM cell growth in vitro [103], drugs targeting signal pathways connected with the receptor for vascular endothelial growth factor — VEGFR [104] or PD-1 inhibitors, prolonging survival in mouse models of LAM [66].

**Treatment and prognosis in E-LAM**

Lymphangioleiomyomas, even though they attain large sizes and are often non-resectable [29, 45], in general, have a mild clinical course. In a retrospective analysis by Matsui et al. (2001) among 17 patients with E-LAM, only one died because of an aggressive course of a simultaneously occurring pulmonary LAM form, all the others were alive at the moment of publishing the results with an average observation time of 5.5 years [6]. Radical resection allows long-term control of the disease [16, 24, 39, 40, 42, 50], also when laparoscopic techniques are used [43, 113]. There are reports in the literature about local recurrence after E-LAM resection [37, 114], which can, however, be treated with good effects by a repeated resection [115]. Long survival times were also observed in the case of non-resectable disease; the case of an 11-year old girl has been described in whom a non-radically excised mesenterial lymphangioleiomyoma did not undergo progression in spite of lack of treatment for 10 years [116] and a 47-year old woman with uterine E-LAM and metastases to the lungs and ovary who remained in good overall status for 12 years of observation [117]. Because of the lack of unified methods of lymphangioleiomyoma treatment and their relatively mild clinical course, screening of patients with the pulmonary form of LAM for E-LAM is not recommended, if they do not have any clinical symptoms [7]. If cumbersome clinical symptoms occur such as pain in tumor progression, constipation or edema of the lower extremities, attempts to treat are undertaken similar to the pulmonary form of LAM — by hormone therapy [12] and mTOR inhibitors [118] and radiotherapy for the area of the occupied lymph nodes [119]. Radzikowska et al. (2016) performed a retrospective analysis of the effectiveness of sirolimus in 14 patients with pulmonary LAM (including one with TSC) and lymphangioleiomyoma of the retroperitoneal tract [118]. During 10 months of therapy with sirolimus (at
| Author             | Age | TSC | Pulmonary LAM | Localization | Max. tumor diameter | Symptoms from tumor                                                                 | Drug; Dose                  | Best response | Time of observation | Progression |
|--------------------|-----|-----|---------------|--------------|--------------------|-------------------------------------------------------------------------------------|-----------------------------|---------------|---------------------|-------------|
| Chen et al. 2009 [88] | 23  | no  | yes           | PZ           | –                  | –                                                                                   | Sirolimus; 1 mg/d           | –             | 36 months           | No          |
| Possekel et al. 2009 [41] | 23  | no  | no            | Numerous in liver, mesentery, wall of small and large intestine | 10 cm | A feeling of incomplete elimination, stomach pain                                    | Sirolimus; 1.5 Mg/d        | PR            | 3 months            | No          |
| Rosenberg et al. 2013 [121] | 41  | no  | yes           | PZ           | 16.5 cm            | Stomach pain, early feeling of satiety                                              | Sirolimus; –               | PR            | 9 months            | No          |
| Freitas et al. 2015 [122] | 26  | no  | yes           | PZ, abdominal lymph nodes | – | –                                                                                   | Sirolimus; –               | PR            | 12 months           | No          |
|                      | 37  | no  | later         | PZ            | 18 cm              | Pain in the vicinity of tumor                                                       | Sirolimus; 2 mg/d          | PR            | 6 months            | No          |
| Hecimovic et al. 2015 [123] | 44  | no  | yes           | PZ            | 7 cm               | –                                                                                   | Sirolimus; 2-3 mg/d        | PR            | 10 months           | No          |
|                      | 33  | no  | later         | PZ, pelvis    | 10 cm              | –                                                                                   | Sirolimus; 1 mg/d          | PR (almost CR) | 9 months            | No          |
|                      | 34  | no  | later         | PZ            | 8 cm               | Stomach pain, increase in stomach diameter, ascites, hemoptysis                     | Sirolimus; 2 mg/d          | PR            | 3 months            | No          |
| Cabeza et al. 2016 [124] | 53  | no  | yes           | Numerous in PZ | 6.8 cm            | Stomach pain                                                                        | Sirolimus; 2 mg/d          | PR (almost CR) | 12 months           | No          |
| Harrari et al. 2016 [125] | 39  | no  | no            | Numerous in PZ | –                  | –                                                                                   | Sirolimus; 2 Mg/d          | PR            | 18 months           | No          |
| Ito et al. 2016 [126] | 39  | no  | yes           | PZ, pelvis    | 6.2 cm; Edema of lower extremity                                                  | Sirolimus; 1mg/d for 2 weeks then 2 mg/d | PR (almost CR) | 18 months           | No          |
| Wahid et al. 2016 [127] | 37  | yes | no            | pelvis        | 15.3 cm            | Back ache, fainting                                                                | Everolimus; 10mg/d         | PR            | 12 months           | No          |
|                      | 45  | no  | no            | PZ            | 8.5 cm              | Feeling of satiety, pain in vicinity of tumor                                      | Everolimus; 10mg/d         | CR            | 18 months           | No          |
| Lecuelle et al. 2019 [128] | 35  | no  | yes           | PZ            | 8.5 cm              | –                                                                                   | Sirolimus; 5mg/d           | CR            | 30 months           | No          |
| Ussavarugsi et al. 2019 [129] | 26  | no  | yes           | PZ            | 26 cm               | –                                                                                   | Sirolimus; 1 mg/d          | SD            | 14 months           | No          |

CR — complete response; d — day; max. — maximal; PD— disease progression; PR— partial response; PZ — retroperitoneal space
Table 3. E-LAM cases with the use of hormone therapy available in the literature

| Author            | Age | TSC | Pulmonary LAM | Localization                                                                 | Max. tumor diameter | Symptoms from tumor | Drug; Dose                                                                 | Best response | Time of observation | Progression | Drug; Dose |
|-------------------|-----|-----|----------------|-------------------------------------------------------------------------------|---------------------|---------------------|----------------------------------------------------------------------------|---------------|---------------------|-------------|------------|
| Klein et al. 1992 [130] | 36  | No  | Yes            | Mediastinum lymph nodes, pz and pelvis                                       | Numerous — max 5 cm | None                | Oophorectomy + ifn-α2b (for 3 months) + t tamoxifen                     | CR            | 18 months           | No          |            |
| de Groot et al. 2008 [45] | 23  | No  | Later          | Pz                                                                           | 16 cm               | Pain in the vicinity of tumor | Goserelin + tamoxifen as described | PD            | –                   | –           | –          |
| Yokoshita et al. 2011 [131] | 30  | No  | No             | Pelvis                                                                       | –                   | Recurring stomach pains during menstruation | Leuprolin 1.88 mg/ month           | SD            | 6 months            | No          |            |
| Szpurek et al. 2014 [117] | 47  | No  | No             | Uterus, metastases to ovary and lungs                                        | –                   | Brak                | Tamoxifen —                                                        | SD            | 5 months            | Yes         |            |
| Basnet et al. 2015 [132] | 24  | No  | No             | Pz, pelvis, mesentery                                                       | Numerous, approx. 3 cm | Pain in vicinity of tumor | Medroxyprogesterone 150 mg i.m; 2 doses given with a 3 month interval | PR            | 6 months            | Yes         |            |
| Yoshizawa et al. 2019 [133] | 36  | Yes | No             | Uterus                                                                       | –                   | Stomach pain        | Leuprolin —                                                        | PD            | –                   | –           | –          |

CR — complete response; d — day; IFN-α2b — interferon α2b; j — unit; max. — maximum; PD — disease progression; PR — partial response; PZ — retroperitoneal space
1. a dose of 1−5 mg/d, in order to attain blood concentration of the drug at a level of 5−15 ng/mL, besides improvement of respiratory tract ailments, a significant decrease was observed in the volume of the lesions in comparison to the initial value (1603.85 ± 2437.56 cm³ vs. 198.01 ± 315.43 cm³; p = 0.00026), and total withdrawal of lymph from the retroperitoneal space and pleura in 13 of them [118]. In the analysis by Mohammadi et al. (2013), encompassing 5 patients with lymphangioleiomyoma of the abdominal cavity, the effectiveness of everolimus (at a dose 1−1.5 mg/d; in two divided doses) was evaluated [120]. After 6 months of therapy in 4 out of 5 patients a partial or complete response was observed and withdrawal of the ascites [120]. The descriptions in the literature of cases treated with mTOR inhibitors and hormone therapy in E-LAM are presented in Table 2 and Table 3, respectively. It is worth stressing that among the cases presented in Table 2 (mTOR inhibitors), disease progression did not occur in any of the cases during the administration of a drug from this group.

2. Summary

Lymphangioleiomyomatosis is a member of the PEComa (perivascular epithelioid cell tumors) family [2]. In patients with the pulmonary form of LAM, LAM foc have been described in the uterus, adnexa or broad ligament of the uterus and there is the frequent occupation of lymph nodes in the extrapleural space [21]. Lymphangioleiomyoma in computer tomography, in general, has the form of a well-separated solid-cystic lesion, with walls of different thickness and numerous septae [26, 27, 46]. Solid or cystic character is less common [27]. The lesion is generally well separated, but a few lymphangioleiomyomas with infiltrating growth are also observed [18]. Sirolimus is currently the only drug whose use in LAM is recommended by international recommendations [5]. The randomized, multicenter, placebo-controlled, double-blind clinical phase III MILES trial (Multicenter International Lymphangioleiomyomatosis Efficacy And Safety Of Sirolimus), is so far the largest clinical trial concerning the use of sirolimus in LAM [91]. Preclinical and clinical trials also encompass autophagy inhibitors [100], statins [101], hydroxychloroquine [102], anti-VEGFR drugs [104] and PD-1 inhibitors [66].

3. Conflict of interest

The authors report no conflicts of interest.

4. References

Klimczak A, Pejuc M, Wiater K, et al. PEComa — grupa rzadkich nowotworów pochodzenia mezenchymalnego. NOWOTWORY Journal of Oncology. 2011; 61(1): 52–56.

Martignoni G, Pea M, Reghellini D, et al. Molecular pathology of lymphangioleiomyomatosis and other perivascular epithelioid cell tumors. Arch Pathol Lab Med. 2010; 134(1): 33–40, doi: 10.1043/2008-0542-RARI.1, indexed in Pubmed: 20737683.

Thway K, Fisher C. PEComa: morphology and genetics of a complex tumor family. Ann Diagn Pathol. 2015; 19(5): 359–368, doi: 10.1016/j.anndiagpath.2015.06.003, indexed in Pubmed: 26144278.

Stłowierska M, Jóźwick S, Peron A, et al. Early diagnosis of tuberous sclerosis complex: a race against time. How to make the diagnosis before seizures? Orphanet J Rare Dis. 2018; 13(1): 25, doi: 10.1186/s13023-018-0764-2, indexed in Pubmed: 29378663.

McCormack F, Gupta N, Finlay G, et al. Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management. American Journal of Respiratory and Critical Care Medicine. 2016; 194(6): 748–761, doi: 10.1164/rccm.201607-1384st.

Matsui K, Tatsuguchi A, Valencia J, et al. Extrapulmonary lymphangi-oleiomyomatosis (LAM): clinicopathologic features in 22 cases. Hum Pathol. 2000; 31(10): 1242–1248, doi: 10.1016/s0365-676x(00)00762-9, indexed in Pubmed: 2944458.

Johnson SR, Cordier JF, Lazor R, et al. Review Panel of the ERS LAM Task Force. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J. 2010; 35(1): 14–26, doi: 10.1183/09031936.00079209, indexed in Pubmed: 20302056.

Muzykewicz DA, Sharma A, Muse V, et al. TSC1 and TSC2 mutations in patients with lymphangioleiomyomatosis and tuberous sclerosis complex. J Med Genet. 2009; 46(7): 465–468, doi: 10.1136/jmg.2008.063342, indexed in Pubmed: 19419985.

Kebria M, Black D, Borelli C, et al. Primary retroperitoneal lymphangioleiomyomatosis in the UK. Thorax. 2000; 55(12): 1052–1057, doi: 10.1136/thorax.55.12.1052, indexed in Pubmed: 11083892.

Kebede K, Black D, Borelli C, et al. Primary retroperitoneal lymphangi-oleiomyomatosis in a postmenopausal woman: a case report and review of the literature. Int J Gynecol Cancer. 2009; 19(4): 1041–1052, doi: 10.1111/j.1525-1438.2007.07085.x, indexed in Pubmed: 17362325.

Li Y, Guo Z, Zhao C, et al. Lymphangioleiomyomatosis: a case report and review of diagnosis and treatment. Onco Targets Ther. 2018; 11: 5339-5347, doi: 10.2147/OTT.S161360, indexed in Pubmed: 32014240.

Takia L, Jat KR, Mandal A, et al. Lymphangioleiomyomatosis (LAM) presenting as recurrent pneumothorax in an infant with tuberous sclerosis: treated successfully with sirolimus. BMJ Case Rep. 2018; 2018, doi: 10.1136/bcr-2018-226244, indexed in Pubmed: 30413450.

Fiore MG, Sanguedolce F, Lolli I, et al. Abdominal lymphangioleiomyomatosis in a man with Klinefelter syndrome: the first reported case. Ann Diagn Pathol. 2005; 9(2): 98–100, doi: 10.1016/j.anndiagpath.2004.12.007, indexed in Pubmed: 15906517.

Zhang C, Chen X, Wen T, et al. Computed tomography lymphangiographic findings in 27 cases of lymphangioleiomyomatosis. Acta Radiol. 2017; 58(11): 1342–1348, doi: 10.1177/0284185116686831, indexed in Pubmed: 28132530.

Avila NA, Bechtle J, Dwyer AJ, et al. Lymphangioleiomyomatosis: CT of diurnal variation of lymphangioleiomyomas. Radiology. 2001; 221(2): 415–421, doi: 10.1148/radiology.221.2.11523487, indexed in Pubmed: 11687685.

Avila NA, Kelly JA, Chu SC, et al. Lymphangioleiomyomatosis: abdominal pelvic CT and US findings. Radiology. 2000; 216(1): 147–153, doi: 10.1148/ radiology.216.1.10241417, indexed in Pubmed: 10897341.

Torres VE, Björnsson A, King BF, et al. Extrapulmonary lymphangi-oleiomyomatosis and lymphangiomatous cysts in tuberous sclerosis complex. Mayo Clin Proc. 1995; 70(7): 641–648, doi: 10.1016/s0025-6196(96)60584-1, indexed in Pubmed: 7791386.

Hayashi T, Kumakura T, Mitani K, et al. Prevalence of uterine and adnexal involvement in pulmonary lymphangioleiomyomatosis: a clinicopathologic study of 10 patients. Am J Surg Pathol. 2011; 35(12): 1776–1785, doi: 10.1097/PAS.0b013e318235edbd, indexed in Pubmed: 22200403.
24. Pontes M, Barbosa C, Coelho ML, et al. Probable initial pulmonary lymphangioleiomyomatosis: a study of 24 cases with evaluation of diagnostic immunohistochemistry. J Surg Pathol. 2013; 36(1): 1034–1040. doi: 10.1097/PAS.0b013e3182a1b6e0, indexed in PubMed: 23613658.

25. Kim HS, Park MI, Suh KS. Lymphangiomyomatosis arising in the pelvic cavity: a report of 3 cases, including the potentially earliest manifestation of extrapulmonary lymphangioleiomyomatosis. Int J Gynecol Pathol. 2020; 39(3): 227–232. doi: 10.1097/PAS.0000000000001662, indexed in PubMed: 30789500.

26. Abdelkader A, Lam CA, Shahir KS, et al. Retroperitoneal lymphangioleiomyomatosis with lymph node involvement: A pathologic-radiologic correlation of a rare form of myometrial tumor. Ann Diagn Pathol. 2017; 27: 69–73. doi: 10.1016/j.anndiagpath.2017.01.028, indexed in PubMed: 28325364.

27. Avila NA, Deyew AJ, Murphy-Johnson DV, et al. Sonography of lymphangioleiomyomatosis in lymph nodes: demonstration of diurnal variation. AJR Am J Roentgenol. 2001; 176(4): 995–999. doi: 10.2214/ajr.176.4.12191259, indexed in PubMed: 11412357.

28. Ernst JC, Schaeay R, Cary JM. Pelvic lymphangioleiomyomatosis: Atypical precursor to pulmonary disease. Chest. 1994; 106(4): 1267–1269. doi: 10.1378/chest.106.4.1267, indexed in PubMed: 8119823.

29. Avila NA, Deyew AJ, Murphy-Johnson DV, et al. Sonography of lymphangioleiomyomatosis in lymph nodes: demonstration of diurnal variation. AJR Am J Roentgenol. 2001; 176(4): 995–999. doi: 10.2214/ajr.176.4.12191259, indexed in PubMed: 11412357.

30. Matsui K, Tatsuguchi A, Valencia J, et al. Lymphangioleiomyomatosis (LAM): a review of clinical and morphological features. J Nippon Med Sch. 2013; 80(6): 335–339. doi: 10.1278/jnms.2013.80.6.335, indexed in PubMed: 24192030.

31. Jaiswal VR, Baird J, Fleming J, et al. Localized retroperitoneal lymphangioleiomyomatosis mimicking malignancy. A case report and review of the literature. Arch Pathol Lab Med. 2003, 127(7): 879–882, indexed in PubMed: 12823048.

32. Gray S, Carrington C, Cormog J. Lymphangioleiomyomatosis: Report of a case with ureteral involvement and chyliuria. Cancer. 1975; 35(2): 490–498.

33. Longacre TA, Hendrickson MR, Kapp DS, et al. Lymphangioleiomyomatosis of the uterus simulating high stage endometrial stromal sarcoma. Gynecol Oncol. 1996; 59(3): 104–110. doi: 10.1016/0090-8258(96)00012-8, indexed in PubMed: 8646880.

34. Sandrini A, Silverstone E, Yates DH. Menstrual cycle variation of retroperitoneal lymphangioleiomyomas in lymphangioleiomyomatosis. Int J Gynaecol Obstet. 2004; 88(2): 140–143. doi: 10.1016/j.ijgo.2004.05.003, indexed in PubMed: 15153329.

35. Koba T, Aral T, Katsu I, et al. Efficacy and safety of transbronchial lung biopsy for the diagnosis of lymphangioleiomyomatosis: A report of 24 consecutive patients. Respir Res. 2016; 17(3): 331. doi: 10.1186/s12931-016-0449-0, indexed in PubMed: 27022942.

36. Grzegorek I, Lerou D, Chabowski M, et al. Immunohistochemical evaluation of pulmonary lymphangioleiomyomatosis. Anticancer Res. 2015; 35(6): 3353–3360, indexed in PubMed: 26206905.

37. Matsui K, Tatsuguchi A, Valencia J, et al. Lymphangioleiomyomatosis (LAM): a review of clinical and morphological features. J Nippon Med Sch. 2000; 67(5): 311–319. doi: 10.1278/jnms.67.311, indexed in PubMed: 11231360.

38. Taveira-DaSilva AM, Pacheco-Rodriguez G, Moss J. The natural history of lymphangioleiomyomatosis mimicking: markers of severity, rate of progression and prognosis. Respir Med. 2010; 104(10): 1498–1507. doi: 10.1016/j.rmed.2010.08.002, indexed in PubMed: 20958410.

39. Zhe X, Schuger L. Combined smooth muscle and melanocytic differentiation in lymphangioleiomyomatosis (LAM). J Histochern Cytochem. 2004; 52(12): 1537–1542. doi: 10.1369/jhc.4A2004.2004, indexed in PubMed: 15557209.

40. Zhang X, Davis WD. Pulmonary lymphangioleiomyomatosis. Arch Pathol Lab Med. 2010; 134(12): 1590–1598. doi: 10.1043/2009-0576- RS1, indexed in PubMed: 21128782.
72. Amaral AF, de Oliveira MR, Dias OM, et al. Tuberous Sclerosis, somatic TSC2 mutations in sporadic pulmonary lymphangioleiomyomatosis. American Journal of Respiratory and Critical Care Medicine. 2013; 187(6): 663–665, doi: 10.1164/ajrccm.187.6.663.

69. Strizheva GD, Carsillo T, Kruger WD, et al. The spectrum of mutations controlling cell growth. Biochem J. 2008; 412(2): 179–190, doi: 10.1042/bj20080281

65. Dongre A, Clements D, Fisher AJ, et al. Cathepsin k in lymphangioleiomyomatosis. American Journal of Clinical Pathology. 2011; 135(1): 78–85, doi: 10.1309/AJCP070022, indexed in Pubmed: 22170529.

64. Gao N, Zhang T, Ji J, et al. The efficacy and adverse events of mTOR inhibitors in lymphangioleiomyomatosis: systematic review

61. Davis JM, Hynek E, Husain AN, et al. Lymphatic endothelial differentiation in pulmonary lymphangioleiomyomatosis cells. J Histchem Cytochem. 2013; 61(8): 580–590, doi: 10.1038/000215143483113, indexed in Pubmed: 23605277.

59. Gao L, Yue MM, Davis J, et al. In pulmonary lymphangioleiomyomatosis expression of progestrone receptor is frequently higher than that of estrogen receptor. Virchows Arch. 2014; 464(4): 495–503, doi: 10.1007/s00428-014-1559-9, indexed in Pubmed: 25240892.

58. Flavin R, Cook J, Fiorentino M, et al. J-Catenin is a Useful Adjunct Immunohistochemical Marker for the Diagnosis of Pulmonary Lymphangioleiomyomatosis. American Journal of Clinical Pathology. 2011; 135(9): 776–782, doi: 10.1309/AJCP12015.

57. Dongre A, Clements D, Fisher AJ, et al. Cathepsin k in lymphangioleiomyomatosis. Lymphat Res Biol. 2010; 8(1): 33–42, doi: 10.1189/lrb.2009.014, indexed in Pubmed: 20742191.

56. Smolak TE, Wesser LL, McCormack FX, et al. Evidence that lymphangioleiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangioleiomyomatosis. Am J Hum Genet. 1998; 62(4): 810–815, doi: 10.1006/jmgh.1998.0335, indexed in Pubmed: 9529362.

55. Kristof AS, You Z, Han YS, et al. mTOR signaling in lymphangiomyomatosis. Am J Hum Genet. 1998; 62(4): 810–815, doi: 10.1006/jmgh.1998.0335, indexed in Pubmed: 9529362.

54. Gao L, Yue MM, Davis J, et al. Lymphatic endothelial differentiation in pulmonary lymphangioleiomyomatosis cells. J Histchem Cytochem. 2013; 61(8): 580–590, doi: 10.1038/000215143483113, indexed in Pubmed: 23605277.

53. Gao L, Yue MM, Davis J, et al. In pulmonary lymphangioleiomyomatosis expression of progestrone receptor is frequently higher than that of estrogen receptor. Virchows Arch. 2014; 464(4): 495–503, doi: 10.1007/s00428-014-1559-9, indexed in Pubmed: 25240892.

52. Flavin R, Cook J, Fiorentino M, et al. J-Catenin is a Useful Adjunct Immunohistochemical Marker for the Diagnosis of Pulmonary Lymphangioleiomyomatosis. American Journal of Clinical Pathology. 2011; 135(9): 776–782, doi: 10.1309/AJCP12015.

51. Dongre A, Clements D, Fisher AJ, et al. Cathepsin k in lymphangioleiomyomatosis. Lymphat Res Biol. 2010; 8(1): 33–42, doi: 10.1189/lrb.2009.014, indexed in Pubmed: 20742191.

50. Smolak TE, Wesser LL, McCormack FX, et al. Evidence that lymphangioleiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangioleiomyomatosis. Am J Hum Genet. 1998; 62(4): 810–815, doi: 10.1006/jmgh.1998.0335, indexed in Pubmed: 9529362.

49. Kristof AS, You Z, Han YS, et al. mTOR signaling in lymphangiomyomatosis. Am J Hum Genet. 1998; 62(4): 810–815, doi: 10.1006/jmgh.1998.0335, indexed in Pubmed: 9529362.

48. Gao L, Yue MM, Davis J, et al. Lymphatic endothelial differentiation in pulmonary lymphangioleiomyomatosis cells. J Histchem Cytochem. 2013; 61(8): 580–590, doi: 10.1038/000215143483113, indexed in Pubmed: 23605277.

47. Davis JM, Hynek E, Husain AN, et al. Lymphatic endothelial differentiation in pulmonary lymphangioleiomyomatosis cells. J Histchem Cytochem. 2013; 61(8): 580–590, doi: 10.1038/000215143483113, indexed in Pubmed: 23605277.

46. Gao L, Yue MM, Davis J, et al. In pulmonary lymphangioleiomyomatosis expression of progestrone receptor is frequently higher than that of estrogen receptor. Virchows Arch. 2014; 464(4): 495–503, doi: 10.1007/s00428-014-1559-9, indexed in Pubmed: 25240892.

45. Flavin R, Cook J, Fiorentino M, et al. J-Catenin is a Useful Adjunct Immunohistochemical Marker for the Diagnosis of Pulmonary Lymphangioleiomyomatosis. American Journal of Clinical Pathology. 2011; 135(9): 776–782, doi: 10.1309/AJCP12015.

44. Dongre A, Clements D, Fisher AJ, et al. Cathepsin k in lymphangioleiomyomatosis. Lymphat Res Biol. 2010; 8(1): 33–42, doi: 10.1189/lrb.2009.014, indexed in Pubmed: 20742191.

43. Smolak TE, Wesser LL, McCormack FX, et al. Evidence that lymphangioleiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangioleiomyomatosis. Am J Hum Genet. 1998; 62(4): 810–815, doi: 10.1006/jmgh.1998.0335, indexed in Pubmed: 9529362.

42. Kristof AS, You Z, Han YS, et al. mTOR signaling in lymphangiomyomatosis. Am J Hum Genet. 1998; 62(4): 810–815, doi: 10.1006/jmgh.1998.0335, indexed in Pubmed: 9529362.

41. Gao L, Yue MM, Davis J, et al. Lymphatic endothelial differentiation in pulmonary lymphangioleiomyomatosis cells. J Histchem Cytochem. 2013; 61(8): 580–590, doi: 10.1038/000215143483113, indexed in Pubmed: 23605277.
117. Mboyo A, Flurin V, Foulet-Roge A, et al. Conservative treatment of a miliary infection in lymphangioleiomyomatosis. Eur J Radiol. 2017; 85(7): e158-e162.

118. Radzikowska E, Przerwa KB, SkroAska P. Lymphangiomyoma in patients with pulmonary lymphangioleiomyomatosis. Am J Clin Pathol. 2014; 141(1): 121–123, doi: 10.1378/ajcp.12.11567.

119. Klein M, Krieger O, Ruckser R, et al. Treatment of lymphangioleio-
ymatosis with sirolimus. Lymphology. 2015; 48(2): 97–102, indexed in Pubmed: 26176626.

120. Cecere L, Ruiz-Cobos M, Casanova A. Resolution of thoracic and abdominal lymphangioleiomyomas in a patient with lymphangio-
leiomyomatosis treated with sirolimus. J Pediatr Surg. 2015; 50(5): 603–607, doi: 10.1016/j.jpedsurg.2015.08.015, indexed in Pubmed: 26522119.

121. Radzikowska E, Przerwa KB, Skroska P. Lymphangioleiomyoma in patients with pulmonary lymphangioleiomyomatosis. Arch Pathol Lab Med. 2014; 138(9): e419-e423, doi: 10.1001/2014.10.1.2015; 151(6): 1302–1310, doi: 10.1016/j.jtho.2017.01.033, indexed in Pubmed: 28182114.

122. Freitas CS, Baldi BG, Araujo MS, et al. Use of sirolimus in the treatment of lymphangioleiomyomatosis: favorable responses in patients with different extrapulmonary manifestations. J Bras Pneumol. 2015; 41(3): 275–280, doi: 10.1590/S1809-371320150003035, indexed in Pubmed: 26175714.

123. Ito T, Suno M, Sakamoto K, et al. Therapeutic effect of sirolimus for abdominal lymphangioleiomyomatosis in an 11-year-old girl with sporadic lymphangioleiomyomatosis. Med J Aust. 2013; 199(2): 121–123, doi: 10.5694/mja12.11567.

124. Rozenberg D, Basile AS, Basile LA, et al. Efficacy of sirolimus treatment for patients with pulmonary lymphangioleiomyomatosis. Respir Care. 2017; 62(5): 606–612, doi: 10.4172/1948-5956.1000352.

125. El-Chemaly S, Taveira-Dasilva A, Goldberg HJ, et al. Sirolimus and Autophagy Inhibition in Lymphangioleiomyomatosis: Results of a Phase I Clinical Trial. Chest. 2017; 151(6): 1302–1310, doi: 10.1016/j.chest.2017.01.033, indexed in Pubmed: 28182114.

126. Ito T, Suno M, Sakamoto K, et al. Therapeutic effect of sirolimus for abdominal lymphangioleiomyomatosis in an 11-year-old girl with sporadic lymphangioleiomyomatosis. Med J Aust. 2013; 199(2): 121–123, doi: 10.5694/mja12.11567.

127. Atochina-Vasserman EN, Abramova E, James ML, et al. Pharmacological targeting of VEGR signaling with astaxin inhibits Tsc2-null lesion growth in the mouse model of lymphangioleiomyomatosis. Am J Physiol Lung Cell Mol Physiol. 2015; 309(2): L1447–L1454, doi: 10.1152/ajplung.00262.2015, indexed in Pubmed: 26439999.

128. Lecuelle D, Basille D, Renard C, et al. Highly effective sirolimus therapy in lymphangioleiomyomatosis: results of a Phase I Clinical Trial. Chest. 2017; 151(6): 1302–1310, doi: 10.1016/j.chest.2017.01.033, indexed in Pubmed: 28182114.

129. Ussavarungsi K, Laroia AT, Burger CD. Low-dose sirolimus in lymphangioleiomyomatosis—two cases report. Pol J Pathol. 2006; 57(4): 205–207, indexed in Pubmed: 17285764.

130. Klein M, Krieger O, Ruckser R, et al. Treatment of lymphangio-
leiomyomatosis due to ovarian hyperstimulation syndrome. J Pediatr Gastroenterol Nutr. 2017; 64(3): 359–365, doi: 10.1097/MPG.0000000000001677.

131. Ding Y, Yan S, Tian Y, et al. Primary abdominal lymphangiolei-
omyomatosis: report of a case. World J Surg Oncol. 2015; 13: 93, doi: 10.1186/s12957-015-0512-y, indexed in Pubmed: 25888993.

132. Saltiel AR, Frye R, Kim J. Autophagy and the regulation of metabolism. Annu. Rev. Biochem. 2015; 84: 721–745, doi: 10.1146/annurev-biochem-060614-020134.

133. Ussavarungsi K, Laroia AT, Burger CD. Low-dose sirolimus in lymphangioleiomyomatosis—two cases report. Pol J Pathol. 2006; 57(4): 205–207, indexed in Pubmed: 17285764.